Performance of drug resistance assays in testing HIV-1 non-B subtypes.
Antiretroviral susceptibility analyses were performed in plasma samples collected from 32 HIV-1 non-B-infected individuals, most of whom had received antiretroviral drugs. Reverse transcriptase (RT) and protease gene sequences were obtained, and 15 anti-HIV drugs were tested in a recombinant virus phenotypic assay. Phenotypic results were obtained in 25 (78.1%) samples, while genotypic data were recorded in 19 (59.4%). In seven samples (21.9%), neither genotypic nor phenotypic results were obtained. Ten of 13 samples with plasma HIV RNA below 2000 copies/mL did not yield genotypic results. Resistance assays work accurately when testing HIV-1 non-B subtypes. However, as for subtype B variants, a low viral load is the most important factor limiting the application of these tests.
Holguín
A
A
Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain.
Hertogs
K
K
Soriano
V
V
D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D005500:Follow-Up Studies; D005838:Genotype; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D015497:HIV-1 / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D010641:Phenotype; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase